-
Je něco špatně v tomto záznamu ?
Salivary microRNAs identified by small RNA sequencing as potential predictors of response to intensity-modulated radiotherapy in head and neck cancer patients
P. Ahmad, M. Slavik, K. Trachtova, NA. Gablo, T. Kazda, D. Gurin, P. Smilek, Z. Horakova, B. Gal, M. Hermanova, P. Slampa, J. Sana, O. Slaby,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
Grantová podpora
15-31627A
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Medline Complete (EBSCOhost)
od 2011-02-01 do Před 1 rokem
Springer Nature OA/Free Journals
od 2011-02-01
- MeSH
- doba přežití bez progrese choroby MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikro RNA genetika metabolismus MeSH
- nádory hlavy a krku genetika radioterapie MeSH
- proporcionální rizikové modely MeSH
- radioterapie s modulovanou intenzitou * MeSH
- sekvenční analýza RNA * MeSH
- senioři MeSH
- sliny metabolismus MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: Progress in radiation therapy of head and neck squamous cell carcinomas (HNSCCs) is logically linked to the development of molecular predictors that would help to enhance individually tailored treatment. MicroRNA (miRNA) expression profiles in tumors have repeatedly been tested to optimize the molecular diagnostics of HNSCC. In addition to tumor tissues, miRNAs are stably present in body fluids, including saliva, and can thus be collected non-invasively. The aim of our current study was to evaluate whether salivary miRNAs have potential as response predictors in HNSCC patients treated with intensity modulated radiation therapy (IMRT). METHODS: In total 48 HNSCC patients treated by definitive IMRT were enrolled in our prospective study. To identify predictive salivary miRNAs, we used small RNA sequencing in 14 saliva samples of HNSCC patients and qRT-PCR validation of selected miRNA candidates in an independent set of 34 patients. RESULTS: We found that salivary miR-15a-5p and miR-15b-5p exhibited differential levels between patients with and without complete remission (p = 0.025 and p = 0.028, respectively). Subsequent Kaplan-Meier analysis confirmed that patients with higher levels of miR-15a-5p reached a significantly longer locoregional progression-free survival (LPFS) than those with low levels (p = 0.024). Finally, multivariate Cox regression analysis revealed that miR-15a-5p may serve as an independent predictive biomarker of LPFS in HNSCC patients treated with IMRT (HR 0.104; 95% CI 0.004-0.911; p = 0.04). CONCLUSIONS: We conclude that salivary miR-15a-5p may represent a potential biomarker for individualized treatment decision-making in HNSCC patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028116
- 003
- CZ-PrNML
- 005
- 20210114153021.0
- 007
- ta
- 008
- 210105s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13402-020-00507-7 $2 doi
- 035 __
- $a (PubMed)32266559
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Ahmad, Parwez $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 245 10
- $a Salivary microRNAs identified by small RNA sequencing as potential predictors of response to intensity-modulated radiotherapy in head and neck cancer patients / $c P. Ahmad, M. Slavik, K. Trachtova, NA. Gablo, T. Kazda, D. Gurin, P. Smilek, Z. Horakova, B. Gal, M. Hermanova, P. Slampa, J. Sana, O. Slaby,
- 520 9_
- $a PURPOSE: Progress in radiation therapy of head and neck squamous cell carcinomas (HNSCCs) is logically linked to the development of molecular predictors that would help to enhance individually tailored treatment. MicroRNA (miRNA) expression profiles in tumors have repeatedly been tested to optimize the molecular diagnostics of HNSCC. In addition to tumor tissues, miRNAs are stably present in body fluids, including saliva, and can thus be collected non-invasively. The aim of our current study was to evaluate whether salivary miRNAs have potential as response predictors in HNSCC patients treated with intensity modulated radiation therapy (IMRT). METHODS: In total 48 HNSCC patients treated by definitive IMRT were enrolled in our prospective study. To identify predictive salivary miRNAs, we used small RNA sequencing in 14 saliva samples of HNSCC patients and qRT-PCR validation of selected miRNA candidates in an independent set of 34 patients. RESULTS: We found that salivary miR-15a-5p and miR-15b-5p exhibited differential levels between patients with and without complete remission (p = 0.025 and p = 0.028, respectively). Subsequent Kaplan-Meier analysis confirmed that patients with higher levels of miR-15a-5p reached a significantly longer locoregional progression-free survival (LPFS) than those with low levels (p = 0.024). Finally, multivariate Cox regression analysis revealed that miR-15a-5p may serve as an independent predictive biomarker of LPFS in HNSCC patients treated with IMRT (HR 0.104; 95% CI 0.004-0.911; p = 0.04). CONCLUSIONS: We conclude that salivary miR-15a-5p may represent a potential biomarker for individualized treatment decision-making in HNSCC patients.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a nádory hlavy a krku $x genetika $x radioterapie $7 D006258
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x genetika $x metabolismus $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 12
- $a radioterapie s modulovanou intenzitou $7 D050397
- 650 _2
- $a sliny $x metabolismus $7 D012463
- 650 12
- $a sekvenční analýza RNA $7 D017423
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Slavik, Marek $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Trachtova, Karolina $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Gablo, Natalia Anna $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Gurin, Dominik $u 1st Department of Pathology, Medical Faculty, St. Anne´s University Hospital, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Smilek, Pavel $u Department of Otorhinolaryngology and Head and Neck Surgery, Medical Faculty, St. Anne´s University Hospital, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Horakova, Zuzana $u Department of Otorhinolaryngology and Head and Neck Surgery, Medical Faculty, St. Anne´s University Hospital, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Gal, Bretislav $u Department of Otorhinolaryngology and Head and Neck Surgery, Medical Faculty, St. Anne´s University Hospital, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Hermanova, Marketa $u 1st Department of Pathology, Medical Faculty, St. Anne´s University Hospital, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Sana, Jiri $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. sana.jiri@gmail.com. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. sana.jiri@gmail.com. Department of Pathology, University Hospital, Brno, Czech Republic. sana.jiri@gmail.com.
- 700 1_
- $a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. on.slaby@gmail.com. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. on.slaby@gmail.com. Department of Pathology, University Hospital, Brno, Czech Republic. on.slaby@gmail.com.
- 773 0_
- $w MED00205912 $t Cellular oncology (Dordrecht) $x 2211-3436 $g Roč. 43, č. 3 (2020), s. 505-511
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32266559 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153018 $b ABA008
- 999 __
- $a ok $b bmc $g 1608451 $s 1119296
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 43 $c 3 $d 505-511 $e 20200407 $i 2211-3436 $m Cellular oncology (Dordrecht) $n Cell Oncol (Dordr) $x MED00205912
- GRA __
- $a 15-31627A $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20210105
